Coherus BioSciences Announces New Employment Inducement Grants
On February 20, 2024, Coherus BioSciences, Inc.(Nasdaq: CHRS) granted options to purchase an aggregate of 170,000 shares of common stock to three newly hired employees.The options have a per share exercise price of $2.59, which was the closing trading price on the grant date.This includes 150,000 shares for an Executive Vice President level executive and 20,000 shares for two additional non-officer employees.
These grants come as the company, with 97.738509 million shares outstanding and a current price of $2.47, continues to grow and expand its workforce.As Coherus BioSciences strives to innovate and make advancements in the biopharmaceutical industry, it recognizes the importance of attracting top talent to drive its mission forward.
The inducement grants not only serve as a way to incentivize new employees but also demonstrate Coherus BioSciences’ commitment to investing in its team for future success.With a solid foundation in place and a talented workforce, the company is well-positioned to achieve its goals and make a lasting impact in the healthcare sector.
Comments